Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

Anti-TNFα therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFα agent, a nanomolecule comprising a humanized Fab’ antibody fragment against TNFα with a polyethylene glycol tail, is shortly to com...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Theresa, Moots, Robert
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673817/
https://www.ncbi.nlm.nih.gov/pubmed/17722505
_version_ 1782166602218733568
author Barnes, Theresa
Moots, Robert
author_facet Barnes, Theresa
Moots, Robert
author_sort Barnes, Theresa
collection PubMed
description Anti-TNFα therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFα agent, a nanomolecule comprising a humanized Fab’ antibody fragment against TNFα with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
format Text
id pubmed-2673817
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26738172009-04-30 Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol Barnes, Theresa Moots, Robert Int J Nanomedicine Review Anti-TNFα therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFα agent, a nanomolecule comprising a humanized Fab’ antibody fragment against TNFα with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place. Dove Medical Press 2007-03 2007-03 /pmc/articles/PMC2673817/ /pubmed/17722505 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Barnes, Theresa
Moots, Robert
Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
title Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
title_full Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
title_fullStr Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
title_full_unstemmed Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
title_short Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
title_sort targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673817/
https://www.ncbi.nlm.nih.gov/pubmed/17722505
work_keys_str_mv AT barnestheresa targetingnanomedicinesinthetreatmentofrheumatoidarthritisfocusoncertolizumabpegol
AT mootsrobert targetingnanomedicinesinthetreatmentofrheumatoidarthritisfocusoncertolizumabpegol

Ejemplares similares